Grifols (GRFS) Receivables (2010 - 2025)
Grifols (GRFS) reported Receivables of $1.0 billion for Q4 2025, up 21.04% on a YoY basis from $836.7 million in Q4 2024, and up 21.04% quarter-over-quarter from $836.7 million in Q4 2024.
Grifols (GRFS) Receivables (2010 - 2025) Analysis & Trends
Grifols has reported Receivables for 16 years, with the latest figure at $1.0 billion in Q4 2025.
- For the quarter ending Q4 2025, Receivables rose 21.04% year-over-year to $1.0 billion; the trailing twelve-month figure through Dec 2025 stood at $1.0 billion (up 21.04% YoY), and the FY2025 full-year result was $1.0 billion, up 21.04% from the prior year.
- Receivables for Q4 2025 stood at $1.0 billion, up from $836.7 million in the prior quarter.
- The five-year high for Receivables was $1.1 billion in Q4 2023, with the low at $647.4 million in Q4 2021.
- Historically, Receivables has averaged $879.3 million across 5 years, with a median of $836.7 million in 2024.
- Annual changes were most pronounced in 2023 — Receivables grew 29.22% — and 2024, when it retreated 21.86%.
- Grifols' Receivables stood at $647.4 million in 2021, then rose by 28.01% to $828.7 million in 2022, then grew by 29.22% to $1.1 billion in 2023, then dropped by 21.86% to $836.7 million in 2024, then rose by 21.04% to $1.0 billion in 2025.
- The last three Receivables figures came in at $1.0 billion (Q4 2025), $836.7 million (Q4 2024), and $1.1 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 10.46 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 21.18 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 17.72 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 12.48 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 12.21 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 9.14 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 5.33 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 12.59 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 9.52 Bn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - | 1.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.01 Bn |
| Dec 31, 2024 | 836.71 Mn |
| Dec 31, 2023 | 1.07 Bn |
| Dec 31, 2022 | 828.67 Mn |
| Dec 31, 2021 | 647.37 Mn |
| Dec 31, 2020 | 543.20 Mn |
| Dec 31, 2019 | 411.41 Mn |
| Dec 31, 2018 | 412.71 Mn |
| Jun 30, 2018 | 464.64 Mn |
| Dec 31, 2017 | 384.88 Mn |
| Jun 30, 2017 | 429.83 Mn |
| Dec 31, 2016 | 576.36 Mn |
| Sep 30, 2016 | 482.23 Mn |
| Jun 30, 2016 | 561.65 Mn |
| Dec 31, 2015 | 463.58 Mn |
| Sep 30, 2015 | 540.53 Mn |
| Jun 30, 2015 | 576,820.75 |
| Mar 31, 2015 | 624.56 Mn |
| Dec 31, 2014 | 670.10 Mn |
| Dec 31, 2013 | 574.45 Mn |